Amgen Stock News

The global TNF inhibitors market was valued around US$ 40,369.8 Mn in 2017. It is anticipated to expand at a stable CAGR of 2.54% during the forecast period of 2018 to 2026, according to a new report published by Transparency

Marshall Wace LLP lessened its position in Amgen Inc. (NASDAQ:AMGN) by 31.3% during the second quarter, Holdings Channel reports. The fund owned 42,869 shares of the medical research companys stock after selling 19,556 shares during the period. Marshall Wace LLPs holdings in Amgen were worth $10,449,000 at the end of the most recent reporting period. []

Martin Capital Partners LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 23,589 shares of the medical research companys stock after purchasing an additional 192 shares during the quarter. Amgen accounts for about 2.5% of Martin Capital Partners LLCs holdings, making the stock []

Park National Corp OH cut its stake in Amgen Inc. (NASDAQ:AMGN) by 4.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,848 shares of the medical research companys stock after selling 200 shares during the period. Park National Corp OHs holdings in []

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Thursday, October 21st, RTT News reports. Investors of record on Tuesday, November 16th will be paid a dividend of 1.76 per share by the medical research company on Wednesday, December 8th. This represents a $7.04 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of []